Targeted delivery of platinum-taxane combination therapy in ovarian cancer
Graphical abstract
Introduction
Combination chemotherapy is preferred over treatment with single agents to combat most cancers as it targets multiple cell-survival pathways at the same time and delays the onset of resistance. This helps in achieving long-term tumor remission and increases median survival [1]. Cisplatin (CDDP)-based therapy has been the standard treatment for ovarian cancer since its discovery. After paclitaxel (PTX) was shown to be effective in ovarian cancer, multiple clinical trials studied the overall efficacy of CDDP and PTX and found significant benefit over the pre-existing treatments. Since then, this combination has been the treatment of choice for both early stage as well as advanced cases of ovarian cancer [2], [3]. However, administration of two different agents comes with the inconvenience of repeated or extended duration of drug infusion in patients. Moreover, the most extensively used conventional formulation of paclitaxel, Taxol®, utilizes Cremophor EL (polyethoxylated castor oil) that has been linked to significant toxicities including allergic, hypersensitivity and anaphylactic reactions during infusion that require premedication and prolonged peripheral neuropathy. Combining such drugs in one delivery carrier is therefore a well-suited and convenient strategy for controlling the pharmacokinetics and co-delivery of the desired drug ratio in vivo, to maximize the therapeutic potency and minimize drug-associated toxicities.
Cross-linked nanogels have been found to be promising drug carriers to achieve this goal. Being mostly hydrophilic in nature, nanogels are highly biocompatible with a high loading capacity for guest molecules [4]. The nanogel structure can be readily adjusted to integrate features of different materials and, thus, offer advantages for combinatorial encapsulation of drugs with varying physicochemical properties. One of the widespread synthetic techniques for the synthesis of nanogels is the crosslinking of preformed core-shell self-assemblies such as polymer micelles that allows introducing a high degree of spatial organization into the nanogels [4], [5]. Cross-linking is known to impart control over the swelling behavior of the nanogels and thus helps in achieving controlled release of the incorporated cargo, which is an added advantage over the structural integrity imparted to the carrier system upon in vivo administration [4], [6]. The enhanced stability also makes the prolonged circulation of the nanogels possible, which in turn allows for increased drug accumulation at the target site [5], [6], [7], [8], [9].
We have previously described a biodegradable hybrid nanogel carrier system (NG) for the combination of CDDP and PTX for ovarian cancer therapy, which not only mitigated the toxicities associated with the use of free drugs but also improved treatment outcome [10]. However, our system relied solely on the enhanced permeation and retention (EPR) effect to facilitate the delivery of the drug combination to the tumor site [11]. Regardless of the importance and popularity of EPR effect-based drug delivery, this strategy has some limitations related to the inter- and intra-tumor heterogeneity, variations in the density as well as permeability of the tumor vasculature that can affect the accumulation of nanocarriers. One of the popular approaches to circumvent these problems is by surface-functionalization of the drug carrier with ligands that can target receptors with differential expression on the cancer cell surface, which helps in increasing the mean residence time of the delivery system at the tumor site and improving target cell uptake [12], [13], [14], [15]. One such receptor of interest is the folate receptor (FR). Malignant cells, due to their high rate of cell division, have an increased requirement of folic acid (FA), since it is an essential component of cell metabolism and DNA synthesis and repair. To fulfill this higher need of FA, FR is known to be over-expressed in a large number of malignant tissues, including ovarian cancer, compared to normal tissues with the exception of the kidney and choroid plexus [16], [17]. Furthermore, this receptor becomes accessible via the plasma compartment only after the cells lose their polarity owing to malignant transformation which makes it a differential target for cancer tissue that is easily accessible for intravenously administered FA-conjugated systems. Its natural ligand, FA, comes with the advantages of high binding affinity, stability and a simple chemical structure together with ease of availability, making it a suitable targeting ligand for ovarian cancer therapy. FA can thus be successfully conjugated to macromolecular systems without loss of binding affinity to its receptor [18]. Many different agents targeting the folate pathway are currently in clinical development [19]. To date, FA-targeted agents showed significant promise in phase II clinical trials but it has not been confirmed in phase III studies [20], [21], [22]. Accordingly, there is a need for further identification of new therapeutic combinations and refinement of patient selection. To this end, FA-conjugated imaging agents could be used for pre-selection of patients based on the expression of FR [23] and several methods have been already developed for this purpose [24], [25].
Our group has previously demonstrated a tumor-specific delivery and improved anti-cancer effect in vivo of CDDP-loaded NGs decorated with FA targeting groups [26]. In the current study, we designed FA-linked NGs incorporating platinum-taxane combination, and examined whether FR-targeted concurrent delivery of synergistic combination of CDDP and PTX can lead to enhanced therapeutic efficacy compared to nontargeted NG system.
Section snippets
Materials
α-Amino-ω-methoxy poly(ethylene glycol) (mPEG-NH2, Mw = 5000 g mol− 1, Mw/Mn = 1.05) was purchased from Creative PEGWorks Inc., (NC, USA). Fmoc-NH-PEG-NH2 (Mw = 7500 g mol− 1, Mw/Mn = 1.04) was purchased from JenKem technology (TX, USA). CDDP was purchased from Acros Organics (NJ, USA). l-Glutamic acid γ-benzyl ester (BGlu), l-phenylalanine (Phe), 1,2-ethylenediamine (ED), 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDC), paclitaxel, folic acid and other chemicals were purchased from
Preparation and characterization of folate-targeted NGs
Triblock copolymer PEG–PGlu90–PPhe25 was utilized for the synthesis of multi-compartment biodegradable NG. We have previously demonstrated that the incorporation of Phe moieties into PEG-PGlu block copolymers facilitated self-assembly of block copolymers in an aqueous medium, which was ascribed to hydrophobic and π–π stacking interactions of the phenylalanine units, and was essential for solubilization of various hydrophobic compounds [10], [27]. As it was reported, the incorporation of
Conclusion
In this study, we demonstrated that folate-decorated NGs carrying CDDP and PTX drug combination exerted enhanced antitumor efficacy, both in terms of tumor growth inhibition and survival, compared to its nontargeted counterpart in rapidly growing murine model of FR-positive ovarian cancer. This better efficacy was only observed when CDDP and PTX are concurrently delivered to the tumor sites. Our data also indicate that IP administration of FA-(CDDP + PTX)/NG can be more effective in the context
Acknowledgments
We acknowledge the assistance of the Nanomaterials Core Facility of the Center for Biomedical Research Excellence (CoBRE), Nebraska Center for Nanomedicine supported by the Institutional Development Award from the National Institute of General Medical Sciences of the National Institutes of Health under grant number P20GM103480. We also thank the NMR and Flow Cytometry Core Facility (University of Nebraska Medical Center) and Lora Arnold for assistance in the histopathology review. The authors
References (46)
- et al.
Core-crosslinked polymeric micelles: principles, preparation, biomedical applications and clinical translation
Nano Today
(2015) - et al.
Hydrolysable core-crosslinked thermosensitive polymeric micelles: synthesis, characterisation and in vivo studies
Biomaterials
(2007) - et al.
Controlled release of cisplatin from pH-thermal dual responsive nanogels
Biomaterials
(2013) - et al.
Biodegradable hybrid polymer micelles for combination drug therapy in ovarian cancer
J. Control. Release
(2013) - et al.
The EPR effect: unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect
Adv. Drug Deliv. Rev.
(2011) - et al.
To exploit the tumor microenvironment: passive and active tumor targeting of nanocarriers for anti-cancer drug delivery
J. Control. Release
(2010) - et al.
The binding avidity of a nanoparticle-based multivalent targeted drug delivery platform
Chem. Biol.
(2007) - et al.
Reprint of “nanobody—shell functionalized thermosensitive core-crosslinked polymeric micelles for active drug targeting”
J. Control. Release
(2011) - et al.
Localization of the murine reduced folate carrier as assessed by immunohistochemical analysis
Biochim. Biophys. Acta
(2001) - et al.
Folate-mediated delivery of macromolecular anticancer therapeutic agents
Adv. Drug Deliv. Rev.
(2012)
Phase II study of treatment of advanced ovarian cancer with folate-receptor-targeted therapeutic (vintafolide) and companion SPECT-based imaging agent (99mTc-etarfolatide)
Ann. Oncol.
Folate receptor expression in carcinomas and normal tissues determined by a quantitative radioligand binding assay
Anal. Biochem.
Folate-decorated nanogels for targeted therapy of ovarian cancer
Biomaterials
Polypeptide-based nanogels co-encapsulating a synergistic combination of doxorubicin with 17-AAG show potent anti-tumor activity in ErbB2-driven breast cancer models
J. Control. Release
MTT colorimetric assay for testing macrophage cytotoxic activity in vitro
J. Immunol. Methods
Polymeric nanogels as vaccine delivery systems
Nanomedicine
Pharmacological profile of FR260330, a novel orally active inducible nitric oxide synthase inhibitor
Eur. J. Pharmacol.
Molecular cloning of the CA125 ovarian cancer antigen identification as a new mucin, MUC16
J. Biol. Chem.
Characterization of intraperitoneal, orthotopic, and metastatic xenograft models of human ovarian cancer
Mol. Ther.
Mechanisms of drug combinations: interaction and network perspectives
Nat. Rev. Drug Discov.
Intraperitoneal cisplatin and paclitaxel in ovarian cancer
N. Engl. J. Med.
Ovarian cancer: Strategies for overcoming resistance to chemotherapy
Nat. Rev. Cancer
Nanogels as pharmaceutical carriers: finite networks of infinite capabilities
Angew. Chem. Int. Ed. Engl.
Cited by (52)
Magic shotgun over magic bullet for treatment of ovarian cancer via polymeric nanoparticles
2023, Journal of Drug Delivery Science and TechnologyTargeted drug conjugate systems for ovarian cancer chemotherapy
2023, Biomedicine and PharmacotherapyBiomedical,clinical and environmental applications of platinum-based nanohybrids: An updated review
2023, Environmental ResearchLigand-installed polymeric nanocarriers for combination chemotherapy of EGFR-positive ovarian cancer
2023, Journal of Controlled ReleaseLignin, lipid, protein, hyaluronic acid, starch, cellulose, gum, pectin, alginate and chitosan-based nanomaterials for cancer nanotherapy: Challenges and opportunities
2021, International Journal of Biological MacromoleculesNanoparticles in precision medicine for ovarian cancer: From chemotherapy to immunotherapy
2020, International Journal of PharmaceuticsCitation Excerpt :ABCG2 and MDR1 expression in PTX-treated cells was 256-fold and 512-fold, respectively, greater than that in cells treated with PTX-loaded FA/PLGA NPs (Abou-ElNaga et al., 2017). FA is also used to decorate other nanocarriers such as albumin NPs, polyethylene glycol poly (lactic acid) (PEG-PLA) NPs, and hybrid nanogel for targeted delivery of PTX or cisplatin to ovarian cancer cells (Desale et al., 2015; Gawde et al., 2018; Yao et al., 2018). CD44 is a cell-surface glycoprotein hyaluronate receptor that plays a role in tumor stemness, recurrence, and drug resistance in ovarian cancer.